The evaluation of fluid replacement test for the patient with glaucoma and optic neuropathy.

The evaluation of fluid replacement test for the patient with glaucoma and optic neuropathy. - The fluid replacement test for glaucoma and optic neuropathy.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020706

Enrollment

Registered

2016-01-23

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.Glaucoma 2.Optic neuropathy

Interventions

Rapid parenteral fluid replacement(500ml of lactated Ringer and 500ml of maintenance transfusion/hour) for the patient with glaucoma and optic neuropathy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patient with visual field defects. 2. The patient who sufficiently understand visual field test. 3. The patient who can safely undergo MRI.

Exclusion criteria

Exclusion criteria: 1. The patient with hypermagnesemia or hypothyloidism. 2. The patient with lactacidemia, Addison disease, hyperkalemia, azotemia, severe burn or oliguria. 3. The patient with heart failure. 4. The patient with metal in their body or claustrophobia. 5. The patient that is not appropriate as the subject by the judgement of principal researcher.

Design outcomes

Primary

Measure	Time frame
Intraocular pressure before and after a rapid parenteral fluid replacement. Optic nerve sheath diameters measured with MRI before and after a rapid parenteral fluid replacement. Visual fields before and after a rapid parenteral fluid replacement. Visual acuity before and after a rapid parenteral fluid replacement.	—

Countries

Japan

Contacts

Public ContactYasuhiro Shinmei

Hokkaido University Graduate School of Medicine Department of Ophthalmology

yshinmei@med.hokudai.ac.jp011-706-5944

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026